Home / Recalls / Amneal Pharmaceuticals of New York, LLC / D-1345-2020

D-1345-2020 Class II Ongoing

Recalled by Amneal Pharmaceuticals of New York, LLC — Brookhaven, NY

Recall Details

Product Type
Drugs
Report Date
July 1, 2020
Initiation Date
May 29, 2020
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
N/A

Product Description

amneal Metformin Hydrochloride Extended-release Tablets, USP, 500 mg Rx Only, 500 Tablets bottles, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd. Ahmedabad 388213, INDIA Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 NDC 65162-178-50

Reason for Recall

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Distribution Pattern

Nationwide

Code Information

AM180641A 6/30/2020 AM180642A 6/30/2020 AM180643A 6/30/2020 AM180644A 6/30/2020 AM180645A 6/30/2020 AM180646A 6/30/2020 AM180647A 6/30/2020 AM180880A 7/31/2020 AM180881A 7/31/2020 AM180882A 7/31/2020 AM180883A 7/31/2020 AM180884A 7/31/2020 AM180885A 7/31/2020 AM180886A 7/31/2020 AM180887A 7/31/2020 AM180888A 7/31/2020 AM180889A 7/31/2020 AM180936A 7/31/2020 AM180937A 7/31/2020 AM180938A 7/31/2020 AM180939A 7/31/2020 AM180940A 7/31/2020 AM180960A 7/31/2020 AM180961A 7/31/2020 AM180962A 7/31/2020 AM180963A 7/31/2020 AM180964A 7/31/2020 AM180965A 7/31/2020 AM180992A 7/31/2020 AM180993A 7/31/2020 AM180994A 8/31/2020 AM180995A 8/31/2020 AM180996A 8/31/2020 AM180997A 8/31/2020 AM181037A 8/31/2020 AM181038A 8/31/2020 AM181039A 8/31/2020 AM181040A 8/31/2020 AM181041A 8/31/2020 AM181079A 8/31/2020 AM181080A 8/31/2020 AM181081A 8/31/2020 AM181082A 8/31/2020 AM181083A 8/31/2020 AM181084A 8/31/2020 AM181085A 8/31/2020 AM181086A 8/31/2020 AM181087A 8/31/2020 AM181088A 8/31/2020 AM181089A 8/31/2020 AM181093A 8/31/2020 AM181094A 8/31/2020 AM181095A 8/31/2020 AM181096A 8/31/2020 AM181097A 8/31/2020 AM181098A 8/31/2020 AM181099A 8/31/2020 AM181100A 8/31/2020 AM181101A 8/31/2020 AM181102A 8/31/2020 AM181116A 8/31/2020 AM181117A 9/30/2020 AM181129A 8/31/2020 AM181130A 8/31/2020 AM181131A 8/31/2020 AM181132A 8/31/2020 AM181133A 9/30/2020 AM181134A 9/30/2020 AM181135A 9/30/2020 AM181136A 9/30/2020 AM181137A 9/30/2020 AM181138A 9/30/2020 AM181183A 9/30/2020 AM181184A 9/30/2020 AM181185A 9/30/2020 AM181186A 9/30/2020 AM181187A 9/30/2020 AM181188A 9/30/2020 AM181189A 9/30/2020 AM181190A 9/30/2020 AM181235A 9/30/2020 AM181236A 9/30/2020 AM181237A 9/30/2020 AM181238A 9/30/2020 AM181239A 9/30/2020 AM181240A 9/30/2020 AM181242A 9/30/2020 AM181243A 9/30/2020 AM181314A 10/31/2020 AM181315A 11/30/2020 AM190121B 12/31/2020 AM190122B 12/31/2020 AM190713AA 6/30/2021 AM191248A 10/31/2021 AM191249A 10/31/2021 AM200192 1/31/2022 AM200322A 2/28/2022

Other recalls by Amneal Pharmaceuticals of New York, LLC

  • D-0477-2024 Class II — Methylergonovine Maleate Tablets, USP, 0.2mg, 12-count bottle, Rx Only, Distribu (March 25, 2024)
  • D-0442-2024 Class I — Vancomycin Hydrochloride for Oral Solution, USP, 250 mg per 5 mL, packaged as (a (March 21, 2024)
  • D-0327-2024 Class II — Oseltamivir Phosphate for Oral Suspension 6mg/ml, 60 mL (reconstituted) bottle, (February 13, 2024)
  • D-0319-2024 Class II — Phenoxybenzamine Hydrochloride Capsules, USP 10mg, 100-count bottle, Rx only, Ma (January 15, 2024)
  • D-0426-2024 Class II — Divalproex Sodium Extended-release Tablets, USP 250 mg, Rx Only, 100 tablets, Ma (December 26, 2023)
  • D-0090-2024 Class II — Extended Phenytoin Sodium Capsules, USP, 100 mg, 100-count bottle, Distributed b (October 27, 2023)
  • D-0876-2023 Class II — Extended Phenytoin Sodium Capsules, USP, 100 mg, Rx Only, 100 capsules per bottl (May 30, 2023)
  • D-0756-2023 Class III — Methylprednisolone Acetate Injectable Suspension, USP 80 mg/mL, For Intramuscula (May 8, 2023)
  • D-1362-2022 Class II — Divalproex Sodium Extended Release Tablets, USP, 250 mg, packaged in 100-count b (July 27, 2022)
  • D-0233-2022 Class II — Flocinolone Acetonide 0.01% Topical Oil, Body Oil, Rx, packaged in 4 oz. bottle, (November 4, 2021)